Assistant Professor, Department of Dermatology, Yale School of Medicine, Yale University Dr. Ian D. Odell is an Assistant Professor of Dermatology at Yale School of Medicine and Dermatology Director of […]
Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Department of Medicine, Perelman School of Medicine, University of Pennsylvania Dr. David Porter is the Jodi Fisher Horowitz Professor in Leukemia Care […]
Developing a bioavailable DNAseIL3 biologic to degrade pathogenic autoantibodies and treat lupus and related autoimmune diseases.
Repurposing nuclear-penetrating autoantibodies from lupus and scleroderma patients as potent, safe inhibitors of pathogenic NETosis.
Advancing engineered CAR and CAAR T cell therapies across multiple autoimmune diseases through clinical trials, preclinical development, and industry partnerships.
Two Yale studies have identified a promising new antibody therapy and a previously unknown signaling pathway as potential treatments for fibrotic autoimmune diseases including scleroderma, lupus, and graft-versus-host disease.
Yale's Colton Center for Autoimmunity has awarded 2022 grants to six projects spanning lupus, multiple sclerosis, pediatric OCD, and systemic sclerosis — all targeting new diagnostics, therapies, or disease mechanisms.
Yale Medicine Magazine profiles Colton-funded researchers using skin as a diagnostic and therapeutic entry point into autoimmune disease — from scleroderma antibody therapy to cancer-triggered bullous pemphigoid.
